PRELUDE THERAPEUTICS INC (PRLD) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -60.49M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-60.49M | (m) |
| 2026-03-31 | (m) | $-77.80M | (m) |
| 2025-12-31 | (m) | $-99.50M | (m) |
| 2025-09-30 | (m) | $-111.77M | (m) |
| 2025-06-30 | (m) | $-124.32M | (m) |
| 2025-03-31 | (m) | $-127.83M | (m) |
| 2024-12-31 | (m) | $-127.17M | (m) |
| 2024-09-30 | (m) | $-131.52M | (m) |
| 2024-06-30 | (m) | $-129.85M | (m) |
| 2024-03-31 | (m) | $-125.55M | (m) |
| 2023-12-31 | (m) | $-121.83M | (m) |
| 2023-09-30 | (m) | $-117.40M | (m) |
| 2023-06-30 | (m) | $-116.75M | (m) |
| 2023-03-31 | (m) | $-113.69M | (m) |
| 2022-12-31 | (m) | $-115.44M | (m) |
| 2022-09-30 | (m) | $-119.64M | (m) |
| 2022-06-30 | (m) | $-120.37M | (m) |
| 2022-03-31 | (m) | $-119.86M | (m) |
| 2021-12-31 | (m) | $-111.69M | (m) |
| 2021-09-30 | (m) | $-98.10M | (m) |
| 2021-06-30 | (m) | $-84.17M | (m) |
| 2021-03-31 | (m) | $-68.72M | (m) |
| 2020-12-31 | (m) | $-56.93M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
| 2019-12-31 | (m) | $-27.57M | (m) |
| 2019-09-30 | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |